Literature DB >> 19430307

Blood and seminal plasma HIV-1 RNA levels among HIV-1-infected injecting drug users participating in the AIDSVAX B/E efficacy trial in Bangkok, Thailand.

Wanitchaya Kittikraisak1, Frits van Griensven, Michael Martin, Janet McNicholl, Peter B Gilbert, Rutt Chuachoowong, Suphak Vanichseni, Ruengpung Sutthent, Jordan W Tappero, Timothy D Mastro, Dale J Hu, Marc Gurwith, Dwip Kitayaporn, Udomsak Sangkum, Kachit Choopanya.   

Abstract

BACKGROUND: We investigated effects of vaccination with AIDSVAX B/E HIV-1 candidate vaccine on blood and seminal plasma HIV-1 RNA viral loads (BVL and SVL, respectively) in vaccine recipients (VRs) and placebo recipients (PRs) who acquired infection.
METHODS: Linear mixed models were fitted for repeated measurements of BVL. Generalized estimating equations were used to assess the difference in SVL detectability between VRs and PRs.
RESULTS: A total of 196 participants became HIV-1 infected during the trial. Thirty-two (16%) became infected with HIV-1 subtype B and 164 (84%) with HIV-1 subtype CRF01_AE. Per protocol-specified analysis, there were no differences in BVL levels between VRs and PRs. When stratified by HIV-1-infecting subtype, vaccination with AIDSVAX B/E was initially associated with higher BVL among HIV-1 CRF01_AE-infected VRs compared with HIV-1 CRF01_AE-infected PRs; however, this difference did not persist over time. HIV-1 subtype B-infected VRs had slightly higher BVL levels and were more likely to have detectable SVL during the follow-up period than HIV-1 subtype B-infected PRs.
CONCLUSIONS: Subtle differences in BVL and SVL were detected between VRs and PRs. These results may help to further understand the dynamics between HIV-1 vaccination, HIV-1-infecting subtypes, and subsequent viral expression in different body compartments.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19430307      PMCID: PMC2764047          DOI: 10.1097/QAI.0b013e3181a44700

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  31 in total

1.  High plasma HIV load in the CRF01-AE outbreak among injecting drug users in Finland.

Authors:  Pia S Kivelä; Anneke Krol; Mika O Salminen; Ronald B Geskus; Jukka I Suni; Veli-Jukka Anttila; Kirsi Liitsola; Veera Zetterberg; Frank Miedema; Ben Berkhout; Roel A Coutinho; Matti A Ristola
Journal:  Scand J Infect Dis       Date:  2005

2.  Rapid and simple method for purification of nucleic acids.

Authors:  R Boom; C J Sol; M M Salimans; C L Jansen; P M Wertheim-van Dillen; J van der Noordaa
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  HIV type 1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity.

Authors:  S Subbarao; K Limpakarnjanarat; T D Mastro; J Bhumisawasdi; P Warachit; C Jayavasu; N L Young; C C Luo; N Shaffer; M L Kalish; G Schochetman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-03-01       Impact factor: 2.205

4.  1997 revised guidelines for performing CD4+ T-cell determinations in persons infected with human immunodeficiency virus (HIV). Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-01-10

5.  Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood.

Authors:  R W Coombs; C E Speck; J P Hughes; W Lee; R Sampoleo; S O Ross; J Dragavon; G Peterson; T M Hooton; A C Collier; L Corey; L Koutsky; J N Krieger
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

6.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

7.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

Authors:  Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para
Journal:  J Infect Dis       Date:  2005-01-27       Impact factor: 5.226

8.  HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine.

Authors:  Peter B Gilbert; Marta L Ackers; Phillip W Berman; Donald P Francis; Vladimir Popovic; Dale J Hu; William L Heyward; Faruk Sinangil; Bryan E Shepherd; Marc Gurwith
Journal:  J Infect Dis       Date:  2005-08-12       Impact factor: 5.226

9.  Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein.

Authors:  Silvija I Staprans; Ashley P Barry; Guido Silvestri; Jeffrey T Safrit; Natalia Kozyr; Beth Sumpter; Hanh Nguyen; Harold McClure; David Montefiori; Jeffrey I Cohen; Mark B Feinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

10.  Early markers of HIV-1 disease progression in a prospective cohort of seroconverters in Bangkok, Thailand: implications for vaccine trials.

Authors:  Kate Buchacz; Dale J Hu; Suphak Vanichseni; Philip A Mock; Thanyanan Chaowanachan; La-ong Srisuwanvilai; Roman Gvetadze; Frits Van Griensven; Jordan W Tappero; Dwip Kitayaporn; Jaranit Kaewkungwal; Kachit Choopanya; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

View more
  3 in total

1.  T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.

Authors:  Ashwini V Shete; Madhuri R Thakar; Srikanth P Tripathy; Cg Raut; Sekhar Chakrabarti; Ramesh S Paranjape
Journal:  J Glob Infect Dis       Date:  2011-07

2.  Rapid dissemination of SIV follows multisite entry after rectal inoculation.

Authors:  Patricia Ribeiro Dos Santos; Magali Rancez; Jean-Luc Prétet; Alice Michel-Salzat; Valérie Messent; Anna Bogdanova; Anne Couëdel-Courteille; Evelyne Souil; Rémi Cheynier; Cécile Butor
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

3.  Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression.

Authors:  Szu-Wei Huang; Sheng-Fan Wang; Yu-Ting Lin; Chia-Hung Yen; Chih-Hao Lee; Wing-Wai Wong; Hung-Chin Tsai; Chia-Jui Yang; Bor-Shen Hu; Yu-Huei Lin; Chin-Tien Wang; Jaang-Jiun Wang; Zixin Hu; Daniel R Kuritzkes; Yen-Hsu Chen; Yi-Ming Arthur Chen
Journal:  PLoS One       Date:  2014-12-11       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.